Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium
Congestive Heart Failure
About this trial
This is an interventional treatment trial for Congestive Heart Failure focused on measuring Extracorporal shock wave therapy, Cell therapy
Eligibility Criteria
Inclusion Criteria: Patients with chronic ischemic heart disease Patients with anterior myocardial infarction > 3months EF < 50% or NYHA II-IV Age 18-80 Informed consent Exclusion Criteria: Ventricular thrombus Infarct < 3 months. Active infection or fever Chronic inflammatory disease (e.g M. Crohn, Rheumatoid Arthritis) HIV Infection oder active Hepatitis Neoplastic disease w/o complete remission within 5 years Stroke < 3months Creatinine > 2 mg/dl Relevant Liver disease (GOT > twice the upper limit). Anemia (Hemoglobin <10 mg/dl) Thrombocytopenia < 100.000/µl Allergies to Aspirin, Clopidogrel, Heparin History of bleeding disorder History of coagulopathy Gastrointestinal Bleeding < 3 months Surgery or Trauma < 2 months Pregnancy Mental Retardation Participation in other clinical study < 1 month
Sites / Locations
- Div. of Cardiology , University of Frankfurt
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Low-dose shock wave treatment & Placebo
low-dose shock-wave treatment & Cell therapy
High-dose shock-wave treatment & Placebo
High-dose shock-wave treatment & cell therapy
Placebo shock-wave treatment & cell therapy